Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
14.70
-0.06 (-0.41%)
At close: Feb 11, 2026, 4:00 PM EST
14.75
+0.05 (0.32%)
After-hours: Feb 11, 2026, 6:02 PM EST
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 8,300 employees as of December 31, 2024. The number of employees increased by 450 or 5.73% compared to the previous year.
Employees
8,300
Change (1Y)
450
Growth (1Y)
5.73%
Revenue / Employee
$353,610
Profits / Employee
$711
Market Cap
4.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8,300 | 450 | 5.73% |
| Dec 31, 2023 | 7,850 | 250 | 3.29% |
| Dec 31, 2022 | 7,600 | 600 | 8.57% |
| Dec 31, 2021 | 7,000 | 1,000 | 16.67% |
| Dec 31, 2020 | 6,000 | 500 | 9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,700 |
| Perrigo Company | 8,379 |
| Phibro Animal Health | 2,475 |
| Alkermes | 1,800 |
| HUTCHMED (China) | 1,780 |
| Hims & Hers Health | 1,637 |
| Lantheus Holdings | 808 |
| Supernus Pharmaceuticals | 674 |
AMRX News
- 14 days ago - Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - GlobeNewsWire
- 15 days ago - TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - PRNewsWire
- 15 days ago - Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - GlobeNewsWire
- 4 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease - Business Wire
- 7 weeks ago - Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - GlobeNewsWire
- 2 months ago - Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
- 2 months ago - Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewsWire